neurocognitive mechanisms underlying smartphone-assisted prevention of relapse in opioid use disorder

Conditions: Opioid-Related Disorders; Mobile Applications; Opiate Substitution Treatment; Magnetic Resonance Imaging; Craving; Attentional Bias; Ecological Momentary Assessment

Summary: the proposed clinical trial would evaluate the use of smartphone applications ("apps", which have well-established efficacy in reducing cigarette and alcohol use) to prevent relapse among patients receiving medication-assisted treatment for opioid use disorder. in addition to standard app-based self-monitoring of drug use and personalized feedback, project innovation is enhanced by the proposed use of location-tracking technology for targeted, personalized intervention when participants enter self-identified areas of high risk for relapse. furthermore, the proposed sub-study would use longitudinal functional neuroimaging to elucidate the brain-cognition relationships underlying individual differences in treatment outcomes, offering broad significance for understanding and enhancing the efficacy of this and other app-based interventions.

the rising public health burden of opioid misuse, coupled with high relapse rates among individuals seeking treatment for opioid use disorder, necessitates novel interventions for improving opioid-related treatment response. mobile technology such as smartphone-based applications ("apps") represent one such intervention. although smartphone apps are effective in reducing cigarette and alcohol use, their efficacy for reducing opioid use has not yet been established. the proposed clinical trial would evaluate the app optimat ("optimizing medication-assisted treatment") to prevent relapse among patients receiving medication-assisted treatment for opioid use disorder. optimat implements two features shown to be effective for reducing substance use: daily self-monitoring of opiate use coupled with personalized feedback. aim 1 would accrue 255 participants with 1:1 randomization into two arms (optimat vs. monitoring only) to evaluate differences in monthly opioid use at six months post-enrollment. aim 2 would enroll a subset of participants (n=120; 60 per arm) into a longitudinal functional neuroimaging (fmri) study to model the neurocognitive mechanisms underlying individual differences in treatment response. two putative mechanisms (attentional bias for drug cues and cue-induced craving) promoting abstinence would be studied. aim 3 would explore the use of location-based geographic ecological momentary assessment (gema) for targeted intervention when participants enter self-identified areas of high risk for relapse. collectively, the proposed aims would (1) evaluate mobile technology applications for reducing opiate use, (2) understand the neurocognitive mechanisms of action to improve upon this and other apps aiming to reduce drug use, and (3) evaluate the role of personalized, contextually-relevant intervention to promote successful treatment outcomes.

Eligibility criteria:
inclusion criteria: * sex: male or female * age: 18 years and older * (mri sub-study): age: 18-50 years old * in phase i treatment of mat for opioid-use disorder. (phase i indicates that patient is receiving no more than one week of take-home medications at each weekly clinic visit.) * must be willing to use a smartphone if randomized to the smartphone intervention arm * (mri sub-study): native english-speaking exclusion criteria: * (mri) medical history: a history of neurological, cardiovascular, or infectious disease would exclude study participation. a loss of consciousness of 20 or more min or other evidence of brain trauma also would be exclusionary. * (mri) pregnancy: a positive test for pregnancy prior to fmri would exclude participation, due to unknown effect of high-field mri on developing fetus. * (mri) mri contraindications: exclusion criteria for mri include (1) the presence of non-removable internal (e.g., cardiac pacemakers, aneurysm clips, artificial joints) or external (e.g., piercings, orthodontics) ferromagnetic objects; (2) claustrophobia in a confined mri environment; (3) medications that interfere with hemodynamic coupling (e.g., beta blockers); (4) hypersensitivity to loud noise; or (5) a body circumference exceeding 60cm due to broad shoulders or morbid obesity